The news is directly related to Lyell Immunopharma and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowered price target may indicate a slightly less optimistic outlook for the company's stock in the short term. However, the overall impact is neutral as the 'Buy' rating suggests that the analyst still sees potential upside.